Subgroup analysis | No. of studies | Summary RR (95Â % CIs) | P* | I2 (%) | P** |
---|---|---|---|---|---|
Summary pooled estimate | 23 | 1.11(0.96–1.29) | <0.001 | 88.8 |  |
Design | Â | Â | Â | Â | 0.025 |
 Case-control | 19 | 1.00(0.95–1.06) | 0.260 | 16.0 |  |
 Cohort | 4 | 1.35(0.93–1.97) | <0.001 | 94.4 |  |
Geographical region | Â | Â | Â | Â | 0.447 |
 North America | 15 | 1.10(0.89–1.36) | <0.001 | 92.1 |  |
 Europe | 7 | 1.09(0.99–1.19) | 0.449 | 0.0 |  |
 Australia | 1 | 1.69(1.23–2.33) | - | - |  |
Period of pregnancy | Â | Â | Â | Â | 0.343 |
Pre-pregnancy or until pregnancy is known | 6 | 0.95(0.88–1.04) | 0.426 | 0.0 |  |
 During pregnancy | 22 | 1.12(0.96–1.30) | <0.001 | 89.3 |  |
  Trimester 1 | 22 | 1.12(0.96–1.30) | <0.001 | 89.3 | |
  Trimester 2 | 12 | 1.22(0.98–1.52) | <0.001 | 90.9 | |
  Trimester 3 | 12 | 1.22(0.98–1.52) | <0.001 | 90.9 | |
Adjusted for smoking | Â | Â | Â | Â | 0.108 |
 Yes | 4 | 1.27(0.86–1.87) | <0.001 | 94.6 |  |
 No | 19 | 1.04(0.96–1.13) | 0.042 | 39.0 |  |